Delivery Order SPE2DB20D9226-SPE2DB25FD1BH
- Not listed
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count packaging). This firm fixed-price delivery order, valued at $4,169.59, was awarded on August 1, 2025, with an ultimate completion date of August 4, 2025. The contract carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, valued at $10,222.72, is scheduled for completion by July 31, 2025, and was issued on July 30, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis. This...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules in quantities of 120 units. This $17,245.40 firm fixed-price delivery order was awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, and carries no set-aside designation. The order falls under DMS Pharmaceutical Group's existing single-award Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency on August 25, 2025, for the supply of Xtandi 40 mg capsules (120-count). The contract carries no set-aside designation and is scheduled for completion by August 26, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,169.59 by the Defense Logistics Agency on August 5, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract utilizes a firm fixed-price delivery order mechanism without a set-aside designation, with an ultimate completion date of August 6, 2025. This award represents a single delivery order executed under DMS...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,565.70 for Xtandi 40mg capsules (120 count) by the Defense Logistics Agency's Medical Supply Chain on September 13, 2025. This firm fixed-price delivery order carries no set-aside designation and is being performed at the awardee's Park Ridge location. The award represents a single delivery order under DMS Pharmaceutical Group's larger...
- SPE2DB20D9226Indefinite Delivery Contract
- SPE2DB20D9226-SPE2DB25FD1BHDelivery Order
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units) with a ceiling value of $8,339.18. This firm fixed-price delivery order, issued on September 11, 2025, with ultimate completion by September 12, 2025, represents a routine pharmaceutical supply transaction under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA. The company holds a significant single-award IDC valued at approximately $500 million through November 2026 under the SPE2DB program, which authorizes the agency to issue delivery orders for a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a crucial supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively in DLA procurement markets without set-aside designations. The company's contract portfolio encompasses an extensive array of medical products ranging from prescription medications to oncology treatments and specialty pharmaceuticals. Xtandi, an oncology treatment, aligns with the company's demonstrated capability to distribute advanced pharmaceutical therapies to Department of Defense healthcare sites, reinforcing its role as a primary distributor of prescription drugs and pharmacy services to military medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.3k | 9/11/25 |